| |
ER+ (n = 785)
| | |
ER- (n = 438)
| | |
|---|
| |
HR
|
95%CI
|
Pval
|
HR
|
95%CI
|
Pval
|
|---|
|
MYC
|
1.5
|
1.16-1.95
|
0.002
|
0.82
|
0.58-1.16
|
0.27
|
|
E2F3
|
2.23
|
1.7-2.92
|
< 10-8
|
0.71
|
0.5-1
|
0.05
|
|
RAS
|
1.38
|
1.06-1.79
|
0.02
|
1.13
|
0.8-1.59
|
0.5
|
|
ERBB2
|
1.06
|
0.82-1.38
|
0.64
|
1.29
|
0.91-1.82
|
0.15
|
|
EGFR
|
0.93
|
0.72-1.21
|
0.59
|
1.82
|
1.28-2.59
|
< 0.001
|
|
AKT
|
1.29
|
0.99-1.67
|
0.06
|
1.49
|
1.05-2.11
|
0.02
|
|
IL12
|
0.88
|
0.68-1.15
|
0.35
|
0.52
|
0.36-0.74
|
< 0.001
|
|
IL4
|
0.96
|
0.74-1.25
|
0.77
|
0.93
|
0.66-1.31
|
0.69
|
|
IL2
|
0.88
|
0.68-1.14
|
0.32
|
0.7
|
0.5-1
|
0.05
|
|
IL13
|
1.28
|
0.98-1.66
|
0.07
|
1.29
|
0.91-1.82
|
0.15
|
|
IFNG
|
1.09
|
0.84-1.42
|
0.5
|
0.58
|
0.41-0.82
|
0.002
|
|
TGFB
|
0.93
|
0.71-1.2
|
0.57
|
1.65
|
1.16-2.34
|
0.004
|
- For ER+ and ER- breast cancers in Set1 and for each pathway, we give the hazard ratio, 95%CI and the log-rank test P-value from a stratified Cox-proportional hazards regression model with cohorts as strata and with distant metastasis free survival (DMFS) as clinical endpoint. Pathway activation levels were divided into high/low activity levels according to values larger/lower than the median. Number of samples is given by n.
